Surgery Partners (SGRY) Q2 Revenue Up 8%

Surgery Partners (NASDAQ:SGRY) reported a mixed Q2 2025, with GAAP revenue of $826.2 million, up 8.4% year-over-year and exceeding analyst estimates, while Adjusted EBITDA grew 9.0% to $129.0 million. However, non-GAAP EPS of $0.17 slightly missed consensus due to higher interest expenses and elevated transaction/IT costs, which also contributed to flat operating cash flow. Despite these bottom-line pressures, the company reaffirmed its full-year 2025 guidance, signaling confidence in its top-line momentum driven by strong case growth and operational efficiencies.

Analysis

Surgery Partners (SGRY) reported a mixed second quarter, characterized by strong top-line performance offset by significant bottom-line pressures. GAAP revenue grew 8.4% year-over-year to $826.2 million, surpassing analyst estimates, driven by a 5.1% increase in same-facility revenue and a 3.8% rise in total case volumes. Adjusted EBITDA also demonstrated strength, increasing 9.0% to $129.0 million with a stable margin of 15.6%. However, these positive operational metrics were undermined by profitability challenges, as non-GAAP EPS of $0.17 missed the $0.18 consensus and marked a 19% decline from the prior year. This earnings miss was primarily attributed to a sharp increase in net interest expense, which reached $67.9 million, and persistently high transaction and integration costs of $18.1 million related to its M&A strategy. The impact of these costs is further evident in the company's cash flow, with year-to-date operating cash flow declining from $123.5 million to $87.3 million. Despite these headwinds, management reaffirmed its full-year 2025 guidance for revenue and Adjusted EBITDA, signaling confidence in its growth trajectory, which is supported by favorable procedural mix shifts toward orthopedics and strong physician recruitment.

Key Decisions for Investors

• Despite the EPS miss, the reaffirmation of full-year guidance and strong top-line performance may present a case for holding or accumulating positions, as the core business growth drivers appear intact.
• Investors should critically monitor the company's ability to manage its debt-related costs and integration expenses, as these are the primary drags on profitability and cash flow.
• Pay close attention to operating cash flow in subsequent quarters, as a failure to improve working capital management and convert strong EBITDA into cash could signal deeper operational issues and hinder deleveraging efforts.
• The balance between high-volume, lower-margin procedures like GI and higher-revenue services such as orthopedics should be watched, as this mix is a key determinant of future margin expansion.